FDA Brief

Warning letters Food

FDA warning letter to

Synaptent, LLC

MediumIssued Nov 9, 2021Posted Dec 7, 2021Office of Human and Animal Food Operations-East 6

FDA warned Synaptent, LLC over website claims that make its supplement products unapproved new drugs and misbranded.

What happened

FDA reviewed www.liftmode.com from August to October 2021 and found the company took orders there for Phenibut FAA, Phenibut HCl, and other listed products. FDA said website claims showed the products were intended to cure, mitigate, treat, or prevent disease or affect body structure or function, making them unapproved new drugs. FDA also said some products were misbranded because they lacked adequate directions or complete serving-size and net-quantity labeling.

What FDA found

  1. Website claims stated the products were intended to treat or prevent disease or affect body structure or function, so they are drugs.

    Section 201(g)(1) of the Act [21 U.S.C. §321(g)(1)]
  2. The products are not generally recognized as safe and effective for those uses and were sold without FDA approval as new drugs.

    Sections 201(p), 301(d), and 505(a) [21 U.S.C. §321(p), §331(d), §355(a)]
  3. Berberine HCL, Magnolia Bark Extract, Tongkat Ali Extract, Tribulus Terrestris Extract, and Garlic Extract lacked adequate directions for use because their intended uses require a licensed practitioner.

    Section 502(f)(1) [21 U.S.C. §352(f)(1)]; 21 CFR 201.5
  4. Baicalin, Curcumin, DHM, and Milk Thistle Extract did not declare a complete serving size in common household measures followed by metric quantity.

    Section 403(q)(1)(A) [21 U.S.C. §343(q)(1)(A)]; 21 CFR 101.9(b)
  5. Baicalin, Curcumin, DHM, and Milk Thistle Extract labels did not express net quantity in pounds and ounces as required.

    21 CFR 101.7(b)(1) and 101.7(j)(1)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to address the violations and prevent recurrence, with supporting documents. If corrective actions cannot be completed in that time, the company must state why and when it will finish; if it disputes the violations, it must provide reasoning and support.

Who should pay attention

  • online supplement retailers selling nootropic or botanical products
  • brands that rely on website disease claims for supplement marketing
  • compliance teams reviewing dietary supplement labeling and claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk